Hyunjin Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hyunjin Park has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Haeryoung Kim
Department of Pathology, Seoul National University College of Medicine, Seoul, Korea
7 shared publications Hyejung Lee
Department of Pathology, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea
3 shared publications- Hee Young Na
Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
2 shared publications Ho-Seong Han
Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
2 shared publications- Kyoung Bun Lee
Department of Biochemistry, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea
2 shared publications - Yangkyu Lee
Department of Pathology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Korea
2 shared publications
Latest Publications
- Open Access
- 20 April 2026
- Published by Korean Society of Gastrointestinal Cancer Research in Journal of Digestive Cancer Research
- Vol. 14 (1) , 93-101
The Role of MicroRNAs in Hepatocellular Carcinoma: From Tumorigenesis to Biomarker Applications
Hyunjin Park, Seunghye Kim, Jeong Eun Yoo, Haeryoung Kim. Journal of Digestive Cancer Research 2026;14:93-101. https://doi.org/10.52927/jdcr.2026.14.1.93
- 20 April 2026
- Published by Korean Society of Gastrointestinal Cancer Research in Journal of Digestive Cancer Research
- Vol. 14 (1) , 93-101
Open AccessThe Role of MicroRNAs in Hepatocellular Carcinoma: From Tumorigenesis to Biomarker Applications
Hyunjin Park, Seunghye Kim, Jeong Eun Yoo, Haeryoung Kim. Journal of Digestive Cancer Research 2026;14:93-101. https://doi.org/10.52927/jdcr.2026.14.1.93
- Open Access
- 16 January 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (3) , 390-396
Nuclear miR-3920 expression in hepatocellular carcinoma is associated with stemness marker expression and poorer prognosis
- 16 January 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (3) , 390-396
Open AccessNuclear miR-3920 expression in hepatocellular carcinoma is associated with stemness marker expression and poorer prognosis
- 4 April 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (7_Suppleme) , 1625
Abstract 1625: A novel SOS1 inhibitor, HM99462 demonstrates antitumor activity against KRAS-mutant cancers
KRAS is a well-known oncogene with the highest mutation rate among various cancers. KRAS cycles between GDP-loaded ‘off’ and GTP-loaded ‘on’ states induce downstream signal transduction to promote cell proliferation and survival. Interconversion between ‘on’ and ‘off’ states is assisted by SOS (Son of sevenless), a binary molecular switch of KRAS. SOS family as a guanine-nucleotide exchange factor (GEF) is composed of SOS1 and SOS2, but SOS1 is a node in the negative feedback regulation of the KRAS pathway while SOS2 is not. Since SOS1 is a direct upstream of KRAS, SOS1 inhibitor has the potential to be a pan-KRAS inhibitor affecting various cancers harboring diverse KRAS mutations. Here, we suggest HM99462 as a novel SOS1 inhibitor for KRAS regulation and present its promising druggability. We developed HM99462 for an orally bioavailable SOS1 inhibitor which abrogates GTP-binding to KRAS and the profile of drug potency and mechanism of action was examined with in vitro and in vivo models. Biochemical activity on SOS1 was evaluated by a GTP-exchange assay on KRAS G12C, D, and V, and HM99462 showed excellent inhibitory activity, while SOS2 action was not affected. Moreover, HM99462 decreased ERK phosphorylation in various cancer cell lines harboring different major KRAS mutation statuses such as KRAS G12C, G12V, G12D, or G13D. Growth inhibition assay was performed using a three-dimensional (3D) conformation culture that mimics the complexity and heterogeneity of tumors and has elevated p-ERK. In this 3D spheroid growth inhibition assay, HM99462 demonstrated significantly effective GI50 against various KRAS mutant cell lines. HM99462 also had almost no inhibition of seven CYP isozymes guided by the FDA, and a low plasma protein binding rate around 80%, offering high unbound drug concentration. Additionally, HM99462 was evaluated in cancer cell xenograft mouse models harboring various KRAS mutations. Reasonable tumor growth inhibition activity was shown within tolerable doses when administered alone. Also, the combination of HM99462 with KRAS G12C or MEK inhibitors led to synergistic anti-tumor activity in both in vitro and in vivo models with several KRAS mutations. Through our exploratory study, a novel SOS1 inhibitor, HM99462 could be suggested as an appropriate therapeutic agent for diverse inhibitory activity against cancers causing by the hyperactivation of oncogenic KRAS signaling. And it has the potential to overcome the limitations of KRAS G12C or MEK inhibitor through combination. HM99462 is currently in IND enabling GLP-toxicity studies, planned to initiate clinical study in early 2024. Citation Format: Seung Hyun Jung, Jaeyul Choi, Wongi Park, Jooyun Byun, Semi Lim, Youngjoo Lee, Yu-Yon Kim, Hyunjin Park, So-Ye Jeon, Taehun Song, Kyungjin Choi, Tae-yeon Kong, Heecheol Kim, Wook Jang, EunYoung Lee, Minhwa Kim, Young Gil Ahn, Young Hoon Kim, Kwee Hyun Suh. A novel SOS1 inhibitor, HM99462 demonstrates antitumor activity against KRAS-mutant cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1625.
- 4 April 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (7_Suppleme) , 1625
Abstract 1625: A novel SOS1 inhibitor, HM99462 demonstrates antitumor activity against KRAS-mutant cancers
KRAS is a well-known oncogene with the highest mutation rate among various cancers. KRAS cycles between GDP-loaded ‘off’ and GTP-loaded ‘on’ states induce downstream signal transduction to promote cell proliferation and survival. Interconversion between ‘on’ and ‘off’ states is assisted by SOS (Son of sevenless), a binary molecular switch of KRAS. SOS family as a guanine-nucleotide exchange factor (GEF) is composed of SOS1 and SOS2, but SOS1 is a node in the negative feedback regulation of the KRAS pathway while SOS2 is not. Since SOS1 is a direct upstream of KRAS, SOS1 inhibitor has the potential to be a pan-KRAS inhibitor affecting various cancers harboring diverse KRAS mutations. Here, we suggest HM99462 as a novel SOS1 inhibitor for KRAS regulation and present its promising druggability. We developed HM99462 for an orally bioavailable SOS1 inhibitor which abrogates GTP-binding to KRAS and the profile of drug potency and mechanism of action was examined with in vitro and in vivo models. Biochemical activity on SOS1 was evaluated by a GTP-exchange assay on KRAS G12C, D, and V, and HM99462 showed excellent inhibitory activity, while SOS2 action was not affected. Moreover, HM99462 decreased ERK phosphorylation in various cancer cell lines harboring different major KRAS mutation statuses such as KRAS G12C, G12V, G12D, or G13D. Growth inhibition assay was performed using a three-dimensional (3D) conformation culture that mimics the complexity and heterogeneity of tumors and has elevated p-ERK. In this 3D spheroid growth inhibition assay, HM99462 demonstrated significantly effective GI50 against various KRAS mutant cell lines. HM99462 also had almost no inhibition of seven CYP isozymes guided by the FDA, and a low plasma protein binding rate around 80%, offering high unbound drug concentration. Additionally, HM99462 was evaluated in cancer cell xenograft mouse models harboring various KRAS mutations. Reasonable tumor growth inhibition activity was shown within tolerable doses when administered alone. Also, the combination of HM99462 with KRAS G12C or MEK inhibitors led to synergistic anti-tumor activity in both in vitro and in vivo models with several KRAS mutations. Through our exploratory study, a novel SOS1 inhibitor, HM99462 could be suggested as an appropriate therapeutic agent for diverse inhibitory activity against cancers causing by the hyperactivation of oncogenic KRAS signaling. And it has the potential to overcome the limitations of KRAS G12C or MEK inhibitor through combination. HM99462 is currently in IND enabling GLP-toxicity studies, planned to initiate clinical study in early 2024. Citation Format: Seung Hyun Jung, Jaeyul Choi, Wongi Park, Jooyun Byun, Semi Lim, Youngjoo Lee, Yu-Yon Kim, Hyunjin Park, So-Ye Jeon, Taehun Song, Kyungjin Choi, Tae-yeon Kong, Heecheol Kim, Wook Jang, EunYoung Lee, Minhwa Kim, Young Gil Ahn, Young Hoon Kim, Kwee Hyun Suh. A novel SOS1 inhibitor, HM99462 demonstrates antitumor activity against KRAS-mutant cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1625.
- Open Access
- 15 September 2021
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 55 (5) , 338-348
Prognostic significance of viable tumor size measurement in hepatocellular carcinomas after preoperative locoregional treatment
Background: Preoperative locoregional treatment (LRT) for hepatocellular carcinoma (HCC) often induces intratumoral necrosis without affecting the overall tumor size, and residual viable tumor size (VTS) on imaging is an important clinical parameter for assessing post-treatment response. However, for surgical specimens, it is unclear whether the VTS would be more relevant to prognosis compared to total tumor size (TTS).Methods: A total of 142 surgically resected solitary HCC cases were retrospectively reviewed. The TTS and VTS were assessed by applying the modified Response Evaluation Criteria in Solid Tumors method to the resected specimens, and correlated with the clinicopathological features and survival.Results: As applying VTS, 13/142 cases (9.2%) were down-staged to ypT1a. Although the survival analysis results for overall survival according to TTS or VTS were similar, VTS was superior to predict disease-free survival (DFS; p = .023) compared to TTS (p = .08). In addition, multivariate analysis demonstrated VTS > 2 cm to be an independent predictive factor for decreased DFS (p = .001). In the subpopulation of patients with LRT (n = 54), DFS in HCCs with TTS or VTS > 2 cm were significantly shorter than those with TTS or VTS ≤ 2 cm (p = .047 and p = .001, respectively). Interestingly, HCCs with TTS > 2 cm but down-staged to VTS ≤ 2 cm after preoperative LRT had similar survival to those with TTS ≤ 2 cm.Conclusions: Although the prognostic impact of tumor size was similar regardless of whether TTS or VTS was applied, reporting VTS may help to increase the number of candidates for surgery in HCC patients with preoperative LRT.
- 15 September 2021
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 55 (5) , 338-348
Open AccessPrognostic significance of viable tumor size measurement in hepatocellular carcinomas after preoperative locoregional treatment
Background: Preoperative locoregional treatment (LRT) for hepatocellular carcinoma (HCC) often induces intratumoral necrosis without affecting the overall tumor size, and residual viable tumor size (VTS) on imaging is an important clinical parameter for assessing post-treatment response. However, for surgical specimens, it is unclear whether the VTS would be more relevant to prognosis compared to total tumor size (TTS).Methods: A total of 142 surgically resected solitary HCC cases were retrospectively reviewed. The TTS and VTS were assessed by applying the modified Response Evaluation Criteria in Solid Tumors method to the resected specimens, and correlated with the clinicopathological features and survival.Results: As applying VTS, 13/142 cases (9.2%) were down-staged to ypT1a. Although the survival analysis results for overall survival according to TTS or VTS were similar, VTS was superior to predict disease-free survival (DFS; p = .023) compared to TTS (p = .08). In addition, multivariate analysis demonstrated VTS > 2 cm to be an independent predictive factor for decreased DFS (p = .001). In the subpopulation of patients with LRT (n = 54), DFS in HCCs with TTS or VTS > 2 cm were significantly shorter than those with TTS or VTS ≤ 2 cm (p = .047 and p = .001, respectively). Interestingly, HCCs with TTS > 2 cm but down-staged to VTS ≤ 2 cm after preoperative LRT had similar survival to those with TTS ≤ 2 cm.Conclusions: Although the prognostic impact of tumor size was similar regardless of whether TTS or VTS was applied, reporting VTS may help to increase the number of candidates for surgery in HCC patients with preoperative LRT.
- Open Access
- 15 March 2021
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 55 (2) , 154-158
Multiple hepatocyte nuclear factor 1A (HNF1A)-inactivated hepatocellular adenomas arising in a background of congenital hepatic fibrosis
- 15 March 2021
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 55 (2) , 154-158
Open AccessMultiple hepatocyte nuclear factor 1A (HNF1A)-inactivated hepatocellular adenomas arising in a background of congenital hepatic fibrosis
- Open Access
- 15 September 2020
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 54 (5) , 378-386
Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer
Recently, molecular classifications of gastric cancer (GC) have been proposed that include TP53 mutations and their functional activity. We aimed to demonstrate the correlation between p53 immunohistochemistry (IHC) and TP53 mutations as well as their clinicopathological significance in GC. Deep targeted sequencing was performed using surgical or biopsy specimens from 120 patients with GC. IHC for p53 was performed and interpreted as strong, weak, or negative expression. In 18 cases (15.0%) with discrepant TP53 mutation and p53 IHC results, p53 IHC was repeated. Strong expression of p53 was associated with TP53 missense mutations, negative expression with other types of mutations, and weak expression with wild-type TP53 (p<.001). The sensitivity for each category was 90.9%, 79.0%, and 80.9%, and the specificity was 95.4%, 88.1%, and 92.3%, respectively. The TNM stage at initial diagnosis exhibited a significant correlation with both TP53 mutation type (p=.004) and p53 expression status (p=.029). The Kaplan-Meier survival analysis for 109 stage II and III GC cases showed that patients with TP53 missense mutations had worse overall survival than those in the wild-type and other mutation groups (p=.028). Strong expression of p53 was also associated with worse overall survival in comparison to negative and weak expression (p=.035). Results of IHC of the p53 protein may be used as a simple surrogate marker of TP53 mutations. However, negative expression of p53 and other types of mutations of TP53 should be carefully interpreted because of its lower sensitivity and different prognostic implications.
- 15 September 2020
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 54 (5) , 378-386
Open AccessPrediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer
Recently, molecular classifications of gastric cancer (GC) have been proposed that include TP53 mutations and their functional activity. We aimed to demonstrate the correlation between p53 immunohistochemistry (IHC) and TP53 mutations as well as their clinicopathological significance in GC. Deep targeted sequencing was performed using surgical or biopsy specimens from 120 patients with GC. IHC for p53 was performed and interpreted as strong, weak, or negative expression. In 18 cases (15.0%) with discrepant TP53 mutation and p53 IHC results, p53 IHC was repeated. Strong expression of p53 was associated with TP53 missense mutations, negative expression with other types of mutations, and weak expression with wild-type TP53 (p<.001). The sensitivity for each category was 90.9%, 79.0%, and 80.9%, and the specificity was 95.4%, 88.1%, and 92.3%, respectively. The TNM stage at initial diagnosis exhibited a significant correlation with both TP53 mutation type (p=.004) and p53 expression status (p=.029). The Kaplan-Meier survival analysis for 109 stage II and III GC cases showed that patients with TP53 missense mutations had worse overall survival than those in the wild-type and other mutation groups (p=.028). Strong expression of p53 was also associated with worse overall survival in comparison to negative and weak expression (p=.035). Results of IHC of the p53 protein may be used as a simple surrogate marker of TP53 mutations. However, negative expression of p53 and other types of mutations of TP53 should be carefully interpreted because of its lower sensitivity and different prognostic implications.
- Open Access
- 15 July 2020
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 14 (4) , 521-528
Higher Tumor Cellularity in Resected Pancreatic Ductal Adenocarcinoma Is a Negative Prognostic Indicator
In Kuk Cho, Haeryoung Kim, Jong-chan Lee, Jongchan Lee, Jaihwan Kim, Soomin Ahn, Hyunjin Park, and Jin-Hyeok Hwang. Gut and Liver 2019;0:. https://doi.org/10.5009/gnl19180
- 15 July 2020
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 14 (4) , 521-528
Open AccessHigher Tumor Cellularity in Resected Pancreatic Ductal Adenocarcinoma Is a Negative Prognostic Indicator
In Kuk Cho, Haeryoung Kim, Jong-chan Lee, Jongchan Lee, Jaihwan Kim, Soomin Ahn, Hyunjin Park, and Jin-Hyeok Hwang. Gut and Liver 2019;0:. https://doi.org/10.5009/gnl19180
- Open Access
- 11 October 2017
- Published by SAGE Publications in Tumor Biology
- Vol. 39 (10)
The prognostic significance of cancer-associated fibroblasts in pancreatic ductal adenocarcinoma
Cancer-associated fibroblasts are abundant in the desmoplastic stroma of pancreatic ductal adenocarcinomas and are considered to play important roles in tumor progression. In this study, we investigated the expression status of secreted protein acidic and rich in cysteine, periostin, fibroblast-activated protein, and the newly developed proCOL11A1 antibody in the stroma of surgically resected pancreatic ductal adenocarcinomas and their prognostic implications. Tissue microarrays were constructed from 155 surgically resected pancreatic ductal adenocarcinomas and paired non-neoplastic pancreata and from another independent set of 48 normal/benign pancreata, and immunohistochemical stains were performed for proCOL11A1, fibroblast-activated protein, secreted protein acidic and rich in cysteine, and periostin. The immunohistochemical stain results were correlated with clinicopathological features and survival data. proCOL11A1, fibroblast-activated protein, secreted protein acidic and rich in cysteine, and periostin expression was significantly increased in the intratumoral stroma of pancreatic ductal adenocarcinomas compared to paired non-neoplastic pancreata (proCOL11A1: 145/155 (93.5%) vs 26/154 (16.9%); fibroblast-activated protein: 139/143 (97.2%) vs 82/132 (62.1%); secreted protein acidic and rich in cysteine: 113/150 (75.3%) vs 49/132 (37.1%); periostin: 135/151 (89.4%) vs 45/135 (33.3%); p < 0.001, all). While the four markers were expressed at lower levels in normal/benign pancreata, there were no significant differences in the expression frequencies among normal pancreas, acute pancreatitis, and chronic pancreatitis. Interestingly, on survival analysis, low intratumoral fibroblast-activated protein+ cancer-associated fibroblast counts (+ cancer-associated fibroblast counts (p = 0.010; hazard ratio 5.2 (95% confidence interval 1.3–21.3)). Similar patterns were seen for proCOL11A and secreted protein acidic and rich in cysteine and overall and disease-free survival, although not statistically significant. In conclusion, we demonstrate that the presence of cancer-associated fibroblasts in the tumor stroma may not always be associated with a poor prognosis as suggested in many studies; on the contrary, it may even be associated with prolonged survival, supporting the recent experimental findings that tumor stroma may have a protective role rather than enhance aggressive behavior.
- 11 October 2017
- Published by SAGE Publications in Tumor Biology
- Vol. 39 (10)
Open AccessThe prognostic significance of cancer-associated fibroblasts in pancreatic ductal adenocarcinoma
Cancer-associated fibroblasts are abundant in the desmoplastic stroma of pancreatic ductal adenocarcinomas and are considered to play important roles in tumor progression. In this study, we investigated the expression status of secreted protein acidic and rich in cysteine, periostin, fibroblast-activated protein, and the newly developed proCOL11A1 antibody in the stroma of surgically resected pancreatic ductal adenocarcinomas and their prognostic implications. Tissue microarrays were constructed from 155 surgically resected pancreatic ductal adenocarcinomas and paired non-neoplastic pancreata and from another independent set of 48 normal/benign pancreata, and immunohistochemical stains were performed for proCOL11A1, fibroblast-activated protein, secreted protein acidic and rich in cysteine, and periostin. The immunohistochemical stain results were correlated with clinicopathological features and survival data. proCOL11A1, fibroblast-activated protein, secreted protein acidic and rich in cysteine, and periostin expression was significantly increased in the intratumoral stroma of pancreatic ductal adenocarcinomas compared to paired non-neoplastic pancreata (proCOL11A1: 145/155 (93.5%) vs 26/154 (16.9%); fibroblast-activated protein: 139/143 (97.2%) vs 82/132 (62.1%); secreted protein acidic and rich in cysteine: 113/150 (75.3%) vs 49/132 (37.1%); periostin: 135/151 (89.4%) vs 45/135 (33.3%); p < 0.001, all). While the four markers were expressed at lower levels in normal/benign pancreata, there were no significant differences in the expression frequencies among normal pancreas, acute pancreatitis, and chronic pancreatitis. Interestingly, on survival analysis, low intratumoral fibroblast-activated protein+ cancer-associated fibroblast counts (+ cancer-associated fibroblast counts (p = 0.010; hazard ratio 5.2 (95% confidence interval 1.3–21.3)). Similar patterns were seen for proCOL11A and secreted protein acidic and rich in cysteine and overall and disease-free survival, although not statistically significant. In conclusion, we demonstrate that the presence of cancer-associated fibroblasts in the tumor stroma may not always be associated with a poor prognosis as suggested in many studies; on the contrary, it may even be associated with prolonged survival, supporting the recent experimental findings that tumor stroma may have a protective role rather than enhance aggressive behavior.
- Open Access
- 10 August 2015
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 49 (5) , 373-381
SALL4 Expression in Hepatocellular Carcinomas Is Associated with EpCAM-Positivity and a Poor Prognosis
There is increasing interest in hepatocellular carcinomas (HCC) expressing "stemness"-related markers, as they have been associated with aggressive behavior and poor prognosis. In this study, we investigated the usefulness of Sal-like protein 4 (SALL4), a recently proposed candidate marker of "stemness." Immunohistochemical stains were performed for SALL4, K19, and epithelial cellular adhesion molecule (EpCAM) on tissue microarrays constructed from 190 surgically resected HCCs, and the results were correlated with the clinicopathological features and patient survival data. Nuclear SALL4 expression was observed in 39/190 HCCs (20.5%), while K19 and EpCAM were expressed in 30 (15.9%) and 92 (48.7%) HCCs, respectively. The nuclear expression was generally weak, punctate or clumped. SALL4 expression was significantly associated with a poor overall survival compared to SALL4-negative HCCs (p = .014) compared to SALL4-negative HCCs. On multivariate analysis adjusted for tumor size, multiplicity, vascular invasion, and pathological tumor stage, SALL4 remained as a significant independent predictor of decreased overall survival (p= .004). SALL4 expression was positively correlated with EpCAM expression (p = .013) but not with K19 expression. HCCs that expressed both SALL4 and EpCAM were associated with significantly decreased overall survival, compared to those cases which were negative for both of these markers (p = .031). Although SALL4 expression was not significantly correlated with other clinicopathological parameters suggestive of tumor aggressiveness, SALL4 expression was an independent predictor of poor overall survival in human HCCs, and was also positively correlated with EpCAM expression.
- 10 August 2015
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 49 (5) , 373-381
Open AccessSALL4 Expression in Hepatocellular Carcinomas Is Associated with EpCAM-Positivity and a Poor Prognosis
There is increasing interest in hepatocellular carcinomas (HCC) expressing "stemness"-related markers, as they have been associated with aggressive behavior and poor prognosis. In this study, we investigated the usefulness of Sal-like protein 4 (SALL4), a recently proposed candidate marker of "stemness." Immunohistochemical stains were performed for SALL4, K19, and epithelial cellular adhesion molecule (EpCAM) on tissue microarrays constructed from 190 surgically resected HCCs, and the results were correlated with the clinicopathological features and patient survival data. Nuclear SALL4 expression was observed in 39/190 HCCs (20.5%), while K19 and EpCAM were expressed in 30 (15.9%) and 92 (48.7%) HCCs, respectively. The nuclear expression was generally weak, punctate or clumped. SALL4 expression was significantly associated with a poor overall survival compared to SALL4-negative HCCs (p = .014) compared to SALL4-negative HCCs. On multivariate analysis adjusted for tumor size, multiplicity, vascular invasion, and pathological tumor stage, SALL4 remained as a significant independent predictor of decreased overall survival (p= .004). SALL4 expression was positively correlated with EpCAM expression (p = .013) but not with K19 expression. HCCs that expressed both SALL4 and EpCAM were associated with significantly decreased overall survival, compared to those cases which were negative for both of these markers (p = .031). Although SALL4 expression was not significantly correlated with other clinicopathological parameters suggestive of tumor aggressiveness, SALL4 expression was an independent predictor of poor overall survival in human HCCs, and was also positively correlated with EpCAM expression.